Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $41.56

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned a consensus rating of “Hold” from the eleven analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $41.5556.

Several equities analysts have commented on the stock. Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. JPMorgan Chase & Co. increased their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Monday, April 6th. Truist Financial lowered their price objective on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. Finally, The Goldman Sachs Group raised their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st.

Agios Pharmaceuticals Stock Up 0.7%

AGIO stock opened at $28.33 on Wednesday. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a fifty day simple moving average of $29.63 and a two-hundred day simple moving average of $29.32. The firm has a market capitalization of $1.68 billion, a P/E ratio of -3.91 and a beta of 0.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. The business’s revenue for the quarter was up 137.7% compared to the same quarter last year. As a group, analysts anticipate that Agios Pharmaceuticals will post -6.17 EPS for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,141 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $109,024.11. Following the completion of the transaction, the chief financial officer owned 54,998 shares in the company, valued at $1,908,980.58. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Krishnan Viswanadhan sold 2,959 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider owned 5,141 shares in the company, valued at approximately $142,919.80. The trade was a 36.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,582 shares of company stock worth $520,405 over the last three months. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $25,000. Assetmark Inc. grew its holdings in shares of Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the last quarter. NewEdge Advisors LLC purchased a new position in Agios Pharmaceuticals in the 1st quarter worth about $40,000. Caitong International Asset Management Co. Ltd bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at about $49,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Agios Pharmaceuticals during the 4th quarter valued at about $72,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.